comparemela.com

Latest Breaking News On - Beth delgiacco - Page 5 : comparemela.com

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing. | June 24, 2022

United statesFrance generalKelsey kirkMichelle greenblattBeth delgiaccoEuropean medicines agencyEuropean commissionEuropean union member statesImmunology innovation programCommittee for medicinal products human useMedicinal productsHuman useUnion member statesInstitut de myologieMyasthenia gravis activitiesDaily living

argenx to Present at Upcoming Investor Conferences

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

New yorkUnited statesNetherlands generalPalos verdesKelsey kirkMichelle greenblattBeth delgiaccoSecurities life sciences conferenceGoldman sachsImmunology innovation programAnnual global healthcareRancho palos verdesLife sciencesGlobe newswire

argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United kingdomKelsey kirkMichelle greenblattBeth delgiaccoSociety for investigative dermatologyImmunology innovation programInvestigative dermatologyAnnual meetingbeingDesmoglein specificb cellsSecondary analysisPemphigus vulgarisAnnual meetingBritish journalHans de haardChief scientific officerPublished translational data

argenx announces results of Annual General Meeting of Shareholders

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Kelsey kirkMichelle greenblattBeth delgiaccoPeter verhaegheJim dalyTim van hauwermeirenWerner lanthalerImmunology innovation programAnnual general meetingVan hauwermeirenGlobe newswireBoard of directorsArgenx se

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2022 Results - Earnings Call Transcript

argenx SE (NASDAQ:NASDAQ:ARGX) Q1 2022 Earnings Conference Call May 5, 2022 8:30 ET Corporate Participants Beth DelGiacco - VP Corporate Communications and Investor Relations Tim Van.

United statesDouglas tsaoRaymond jamesJames gordonDerek archilaLaura sutcliffeAllison bratzelJoon leeTim van hauwermeirenDanielle brillYaron werberAkash tewariPiper sandlerLuc truyenYatin sunejaJoel beatty

vimarsana © 2020. All Rights Reserved.